Voxilaprevir: Difference between revisions
Content deleted Content added
Closing 2020 merge proposal; uncontested objection and no support; see Talk:Sofosbuvir/velpatasvir/voxilaprevir#Merge proposal |
Linking the combination in the lede |
||
Line 59: | Line 59: | ||
}} |
}} |
||
'''Voxilaprevir''' is a [[hepatitis C virus]] (HCV) nonstructural (NS) protein [[NS3 (HCV)|3]]/[[NS4A|4A]] protease inhibitor (by [[Gilead Sciences|Gilead]]) that is used in combination with [[sofosbuvir]] and [[velpatasvir]].<ref name="Heo_2018">{{cite journal | vauthors = Heo YA, Deeks ED | title = Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C | journal = Drugs | volume = 78 | issue = 5 | pages = 577–587 | date = April 2018 | pmid = 29546556 | doi = 10.1007/s40265-018-0895-5 }}</ref> The combination has the trade name [[Vosevi]] and received a positive opinion from the European [[Committee for Medicinal Products for Human Use]] in June 2017.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004350/WC500229884.pdf|publisher=[[European Medicines Agency]]|title=Summary of opinion: Vosevi|date=22 June 2017}}</ref> |
'''Voxilaprevir''' is a [[hepatitis C virus]] (HCV) nonstructural (NS) protein [[NS3 (HCV)|3]]/[[NS4A|4A]] protease inhibitor (by [[Gilead Sciences|Gilead]]) that is used in combination with [[sofosbuvir]] and [[velpatasvir]] ([[Sofosbuvir/velpatasvir/voxilaprevir]]).<ref name="Heo_2018">{{cite journal | vauthors = Heo YA, Deeks ED | title = Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C | journal = Drugs | volume = 78 | issue = 5 | pages = 577–587 | date = April 2018 | pmid = 29546556 | doi = 10.1007/s40265-018-0895-5 }}</ref> The combination has the trade name [[Vosevi]] and received a positive opinion from the European [[Committee for Medicinal Products for Human Use]] in June 2017.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004350/WC500229884.pdf|publisher=[[European Medicines Agency]]|title=Summary of opinion: Vosevi|date=22 June 2017}}</ref> |
||
On 18 July 2017, Vosevi was approved by [[Food and drug administration]].<ref>[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm FDA approves Vosevi for Hepatitis C ]</ref> |
On 18 July 2017, Vosevi was approved by [[Food and drug administration]].<ref>[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm FDA approves Vosevi for Hepatitis C ]</ref> |
Revision as of 06:49, 27 July 2021
Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
PDB ligand | |
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model (JSmol) | |
Density | 1.4±0.1[1] g/cm3 |
| |
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir (Sofosbuvir/velpatasvir/voxilaprevir).[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3]
On 18 July 2017, Vosevi was approved by Food and drug administration.[4]
References
- ^ "voxilaprevir_msds".
- ^ Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556.
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
- ^ FDA approves Vosevi for Hepatitis C